Opening Multiple Sclerosis 2021:Real World Conversation
Multiple Sclerosis 2021:Real World Conversation
- Length
- 33 min
- Level
- Undergraduate
- Recorded
- University of Louisville2021
Chapter 1 of 5: Before the lecture
Weighs early high-efficacy therapy against escalation in multiple sclerosis, and when to stop treatment after sixty.
Clinical management of multiple sclerosis starts from distinguishing active inflammation from progressive axonal loss. Robertson examines multiple sclerosis phenotypes, therapeutic algorithms, the risk of progressive multifocal leukoencephalopathy, and considerations for aging patients. Early high-efficacy therapies target the inflammatory phase to prevent permanent disability, while sequential strategies scale up treatment after failure. The session evaluates when to discontinue disease-modifying therapies in older patients based on waning immune system activity.
Clinical management of multiple sclerosis starts from distinguishing active inflammation from progressive axonal loss. Robertson examines multiple sclerosis phenotypes, therapeutic algorithms, the risk of progressive multifocal leukoencephalopathy, and considerations for aging patients. Early high-efficacy therapies target the inflammatory phase to prevent permanent disability, while sequential strategies scale up treatment after failure. The session evaluates when to discontinue disease-modifying therapies in older patients based on waning immune system activity.
McDonald's Criteria 2017
Retrospective observational study at age 60

This lecture
Talk 81 of 115 of UofL Neurology Grand Rounds.
Choose a node to see how it connects to this lecture. What comes before is on the leftat the top. What comes after is on the rightat the bottom. The ring is what it teaches. People and places are above. Other lectures and books are below.
Press a chosen node again to open it.
Your comment is kept while you sign up.Sign in